Research Analysts Set Expectations for Indivior Q2 Earnings

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Indivior to $0.76 (from $0.74), maintains a "Buy" rating and a $48 price target; the consensus full‑year EPS is $3.00 and the average analyst price target is $39.33.
• Indivior reported Q1 EPS of $0.96 on $317 million in revenue, and the stock trades around $37.66 with a 1‑year range of $10.63–$40.02 and a market capitalization of $4.59 billion (P/E ≈ 19.3).
• About 60.33% of the stock is institutionally owned, and Director Stuart A. Kingsley recently purchased 940 shares, increasing his position by 20.25%.

Indivior PLC (NASDAQ:INDV - Free Report) - Investment analysts at HC Wainwright upped their Q2 2026 EPS estimates for Indivior in a research note issued on Thursday, April 30th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of $0.76 for the quarter, up from their prior forecast of $0.74. HC Wainwright has a "Buy" rating and a $48.00 price target on the stock. The consensus estimate for Indivior's current full-year earnings is $3.00 per share. HC Wainwright also issued estimates for Indivior's Q3 2026 earnings at $0.78 EPS, Q4 2026 earnings at $0.85 EPS, FY2027 earnings at $3.34 EPS, FY2028 earnings at $3.48 EPS, FY2029 earnings at $3.70 EPS and FY2030 earnings at $3.93 EPS.

Several other equities research analysts have also recently weighed in on INDV. Northland Securities set a $50.00 price target on Indivior in a research report on Tuesday, January 20th. Zacks Research upgraded shares of Indivior from a "hold" rating to a "strong-buy" rating in a research report on Monday, March 16th. Finally, Weiss Ratings cut shares of Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Indivior has an average rating of "Buy" and a consensus price target of $39.33.

Indivior Price Performance

Shares of NASDAQ:INDV opened at $37.66 on Monday. Indivior has a 1 year low of $10.63 and a 1 year high of $40.02. The business's 50-day moving average is $31.84 and its 200-day moving average is $32.53. The company has a market capitalization of $4.59 billion, a price-to-earnings ratio of 19.31 and a beta of 0.90.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The business had revenue of $317.00 million for the quarter.

Institutional Investors Weigh In On Indivior

Several hedge funds have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. raised its position in shares of Indivior by 43.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company's stock valued at $11,395,000 after buying an additional 96,177 shares in the last quarter. Federated Hermes Inc. purchased a new position in Indivior in the third quarter worth $8,120,000. Aberdeen Group plc purchased a new position in Indivior in the third quarter worth $3,875,000. Victory Capital Management Inc. bought a new position in Indivior in the third quarter valued at $19,437,000. Finally, Claret Asset Management Corp raised its position in Indivior by 5.4% during the third quarter. Claret Asset Management Corp now owns 784,588 shares of the company's stock valued at $18,916,000 after purchasing an additional 40,306 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Indivior

In other Indivior news, Director Stuart A. Kingsley purchased 940 shares of the company's stock in a transaction dated Friday, March 6th. The stock was purchased at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the transaction, the director owned 5,582 shares in the company, valued at $177,842.52. The trade was a 20.25% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.74% of the stock is currently owned by insiders.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.